Evidence map›Paper›PMID 19646987›Full record

ArticleJournal of immunological methods2009

MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis.

Gopalan Soman, Xiaoyi Yang, Hengguang Jiang, Steve Giardina, Vinay Vyas, George Mitra, Jason Yovandich, Stephen P Creekmore, Thomas A Waldmann, Octavio Quiñones and 1 more

Abstract readValidation Study
In one paragraph

Article in Journal of immunological methods, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Refined control of CRISPR-Cas9 gene editing inFrontiers in immunology · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Expression and prognostic value of Ars2 in hepatocellular carcinoma.International journal of clinical oncology · 2014
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gopalan SomanDepartment of Process Analytics, Biopharmaceutical Development Program, SAIC-Frederick, Inc., United States. somang@mail.nih.gov
Xiaoyi Yang
Hengguang Jiang
Steve Giardina
Vinay Vyas
George Mitra
Jason Yovandich
Stephen P Creekmore
Thomas A Waldmann
Octavio Quiñones
W Gregory Alvord

Funding

Interleukin-15 Production for Treatment of Patients with Metastatic MalignancyZIBBC010906 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WALDMANN, THOMAS · 2009 to 2022
$29.3M
NCI NIH HHS HHSN2612008000016CNCI NIH HHS N01 CO012400NCI NIH HHS N01-CO-12400
6 · The paper itself

Abstract

A colorimetric cell proliferation assay using soluble tetrazolium salt [(CellTiter 96(R) Aqueous One Solution) cell proliferation reagent, containing the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) and an electron coupling reagent phenazine ethosulfate], was optimized and qualified for quantitative determination of IL-15 dependent CTLL-2 cell proliferation activity. An in-house recombinant Human (rHu)IL-15 reference lot was standardized (IU/mg) against an international reference standard. Specificity of the assay for IL-15 was documented by illustrating the ability of neutralizing anti-IL-15 antibodies to block the product specific CTLL-2 cell proliferation and the lack of blocking effect with anti-IL-2 antibodies. Under the defined assay conditions, the linear dose-response concentration range was between 0.04 and 0.17ng/ml of the rHuIL-15 produced in-house and 0.5-3.0IU/ml for the international standard. Statistical analysis of the data was performed with the use of scripts written in the R Statistical Language and Environment utilizing a four-parameter logistic regression fit analysis procedure. The overall variation in the ED(50) values for the in-house reference standard from 55 independent estimates performed over the period of 1year was 12.3% of the average. Excellent intra-plate and within-day/inter-plate consistency was observed for all four parameter estimates in the model. Different preparations of rHuIL-15 showed excellent intra-plate consistency in the parameter estimates corresponding to the lower and upper asymptotes as well as to the 'slope' factor at the mid-point. The ED(50) values showed statistically significant differences for different lots and for control versus stressed samples. Three R-scripts improve data analysis capabilities allowing one to describe assay variations, to draw inferences between data sets from formal statistical tests, and to set up improved assay acceptance criteria based on comparability and consistency in the four parameters of the model. The assay is precise, accurate and robust and can be fully validated. Applications of the assay were established including process development support, release of the rHuIL-15 product for pre-clinical and clinical studies, and for monitoring storage stability.

Indexed as

AntibodiesBiological AssayCell Line, TumorCell ProliferationColorimetryEnzyme-Linked Immunosorbent AssayHumansInterleukin-15Interleukin-2Recombinant ProteinsReproducibility of ResultsSensitivity and SpecificityTetrazolium SaltsThiazoles3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoliumAntibodiesIL2 protein, humanInterleukin-15Interleukin-2Recombinant ProteinsTetrazolium SaltsThiazoles

Identifiers

PMID19646987
PMCPMC2786060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.